Evidence map›Paper›PMID 39177710›Full record

ArticleMolecular diversity2025

Design, synthesis, biological evaluation and in silico study of N-(Pyrimidin-2-yl)alkyl/arylamide derivatives as quorum sensing inhibitors against Pseudomonas aeruginosa.

Nikki, Abhinetra Jagdish Bhopale, Kusum Kharga, Nanaji Yerramsetti, Rajnish Kumar, Lokender Kumar, Ashok Kumar Yadav

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

NikkiUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
Abhinetra Jagdish BhopaleDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.), Varanasi, Uttar Pradesh, 221005, India.
Kusum KhargaSchool of Biotechnology, Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Nanaji YerramsettiFiber and Biopolymer Research Institute, Department of Plant and Soil Science, Texas Tech University, Lubbock, TX, 79409-2122, USA.
Rajnish KumarDepartment of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.), Varanasi, Uttar Pradesh, 221005, India.
Lokender KumarSchool of Biotechnology, Faculty of Applied Sciences and Biotechnology, Shoolini University, Solan, Himachal Pradesh, 173229, India.
Ashok Kumar YadavUniversity Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India. ashoky@pu.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of bacterial resistance to antimicrobial agents poses a serious threat to the effectiveness of treating bacterial illnesses. A major factor contributing to antimicrobial resistance is biofilm formation, driven by quorum sensing (QS). QS suppression inhibits the QS signaling pathway, obstructing cell-to-cell communication. This study focuses on N-(pyrimidin-2-yl)alkyl/arylamide derivatives, which were designed, synthesized, and characterized for their QS inhibitory effects. Among the synthesized compounds (3a-j), compounds 3b, 3d, and 3h exhibited the highest QS inhibitory activity, with inhibition zones of 17.66 ± 6.17, 14.00 ± 6.24, and 17.33 ± 0.66 mm, respectively. Further, molecular docking studies revealed binding affinities between - 8.4 and - 6.3 kcal/mol, indicating strong interactions with the target proteins. Moreover, molecular dynamic simulations confirmed the stability of the protein-ligand complexes for compounds 3b and 3 h. Additionally, in-silico methods were employed to predict the physicochemical properties of these molecules. Overall, these findings underscore the potential of N-(pyrimidin-2-yl)alkyl/arylamide derivatives as QS inhibitors, offering a new perspective for developing alternative antimicrobial therapies.

Indexed as

AmidesAnti-Bacterial AgentsDrug DesignPseudomonas aeruginosaPyrimidinesQuorum SensingMicrobial Sensitivity TestsMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipAmidesAnti-Bacterial AgentsPyrimidinesAnti-Quorum sensing activityIn silico studyN-(Pyrimidin-2-yl)alkyl/arylamidesQuorum sensingSynthesis

Identifiers

PMID39177710

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.